Microencapsulated feruloyl esterase producing lactobacilli ameliorate lipid profiles and glycaemia in high fat diet-induced obese mice

RUSSO M; MARQUEZ, ANTONELA; ABEIJÓN-MUKDSI, MARIA; SANTACRUZ, ARLETTE; LÓPEZ-MALO AURELIO; GAUFFIN-CANO, PAOLA; MEDINA, ROXANA

Beneficial Microbes

Wageningen Academic Publishers

Lugar: Gelderland ; Año: 2019

1876-2883

ABSTRACTThe effect of oral administration of spraydried microcapsules of feruloyl esterase (FE)producing Lactobacillus fermentum CRL1446 (Lf) and Lactobacillus johnsonii CRL1231 (Lj)on high fat dietinduced obese mice was investigated to evaluate whether these strains couldbe used as a biotherapeutic for obesity. Swiss albino mice were divided into a normal diet fedgroup receiving empty microcapsules (control), a high fat diet plus empty microcapsules(HFD group), HFD plus microcapsules with Lf (HFDLf group) and HDF plus microcapsuleswith Lj (HFDLj group). Microcapsules containing Lf or Lj at a dose of ~107 cells/day/mousewere given orally for 7 weeks. Body weight gain, adiposity index, plasma leptin, lipidprofiles, glycemia, insulinenia, oral glucose tolerance, intestinal FE, Glutathione peroxidase(GPx) and Glutathione reductase (GR) were determined. Administration of lactobacilli (HFDLf and HFDLj groups) improved metabolic parameters (Triglyceride, Total cholesterol,LDLcholesterol levels) and cardiovascular risk indicators (3746% decreased of atherogenicindex), and reduced body weight gain (29%38%), adiposity index (4262%), plasma leptinlevels, liver weight and fat deposition in liver. Intestinal FE activities significantly increasedin HFDLf (62%) and HFDLj group (48%), thus improving hepatic GR activity (42%increment) compared to HFD group. Moreover, L. johnsonii increased HDLcholesterol andL. fermentum reduced blood glucose to levels similar to the control. These FEproducinglactobacilli have the potential to improve biomarkers involved in obesity by increasingintestinal FE activity.